Research & Development



  張安世等醫者處理好了楊文通的傷勢,這才走到楊文通身邊仔細看看他的傷處,發現醫者已經用塞子將他塌陷的鼻子支撐起來了,就笑道︰“跟匈奴人打交道好,還是跟漢人打交道好?”   奴隸給大漢國帶來了空前的繁榮,同時也隱憂不斷,他原本想利用渾邪王來辨別那些匈奴人是可用的,那些匈奴人是必須除掉的。亿龍彩票下载   “我們沒有漢女美麗!”彩票app大全下载   說完就快快的離開了,這個地方他一刻都不願意再待,原以為十拿九穩的事情,變成目前這個樣子,真是讓人沮喪。   天亮的時候,暴怒的如同野獸一般的周鴻將一千羽林軍分成五隊,繼續追索那些逃遁的匈奴人,只是這一次,他們不僅僅要追捕那些匈奴人,還要追殺那些殺了看守,逃遁無蹤的奴隸。彩票app大全中彩在线   “啊?”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo